1. Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study
- Author
-
Mariola Pęczkowska, Akihiro Sukurai, Anita Špehar Uroić, Andreas Machens, Laura Fugazzola, Tushar Bandgar, Carla Vaz Ferreira Vargas, Hartmut P. H. Neumann, Martin Schlumberger, Delphine Drui, Patricia Fainstein-Day, Francoise Borson Chazot, Amandine Berdelou, Tom R. Kurzawinski, Delphine Mirebeau-Prunier, Olivier Chabre, Dominique Maiter, Philippe Caron, Gabriella Sanso, Tsuneo Imai, Camilo Jimenez, Frederic Sebag, Márta Korbonits, Atila Patocs, Laura Valerio, Sarka Dvorakova, Claudio Letizia, Srivandana Akshintala, Christian Godballe, Regis Cohen, Eric Baudin, Caterina Mian, Jolanta Krajewska, Rossella Elisei, Laurence Leclerc, Tobias Else, Marc Klein, Kornelia Hasse-Lazar, Thierry Brue, Steven G. Waguespack, Petr Vlcek, Nuria Valdes, Thera P. Links, Ana Luisa Maia, Ana O. Hoff, Henning Dralle, Frederic Castinetti, André Lacroix, Xiao Ping Qi, Maria João Bugalho, Maralyn Druce, Nelson Wohllk, Barbara Jarzab, Birke Bausch, Delmar M. Lourenço, John Glod, Shinya Uchino, Caroline Brain, Letizia Canu, Charis Eng, Marta Barontini, Jes Sloth Mathiesen, Antoine Tabarin, Elizabeth G. Grubbs, Lucieli Ceolin, Sandrine Laboureau, Repositório da Universidade de Lisboa, Marseille medical genetics - Centre de génétique médicale de Marseille (MMG), Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), University of Coimbra [Portugal] (UC), Endocrine Section, Hospital del Salvador, Département d'Endocrinologie [CHU Nantes] (Institut du Thorax), Centre hospitalier universitaire de Nantes (CHU Nantes)-Institut du Thorax [Nantes], Queen Mary University of London (QMUL), Centre de médecine nucléaire, Fédération d'endocrinologie-Groupement hospitalier Lyon-Est, Department of Internal Medicine and Medical Specialties, Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome], Biologie du Cancer et de l'Infection (BCI ), Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut National de la Santé et de la Recherche Médicale (INSERM), Università degli Studi di Firenze = University of Florence [Firenze] (UNIFI), Department of Endocrinology and Diabetes Mellitus, Hôpital Delafontaine, CHU Bordeaux [Bordeaux], Endocrinology, Cliniques Universitaires Saint-Luc [Bruxelles], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Department of Medical and Surgical Sciences, Universita degli Studi di Padova, Department of Hypertension, Institute of Cardiology, Service de chirurgie générale et endocrinienne, Hôpital de la Timone [CHU - APHM] (TIMONE), Service d'endocrinologie, diabète, maladies métaboliques [Hôpital de la Conception - APHM], Aix Marseille Université (AMU), Physiopathologie Cardiovasculaire et Mitochondriale (MITOVASC), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Paris-Saclay, Centro de Investigaciones Endocrinológicas, Hospital de Niños R. Gutiérrez, Genomic Medicine Institute, Cleveland Clinic, Médecine nucléaire, Département d'imagerie médicale [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Institut Gustave Roussy (IGR), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Groupement Hospitalier Lyon-Est (GHE), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL)-Fédération d'endocrinologie, Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome] (UNIROMA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Università degli Studi di Firenze = University of Florence (UniFI), Università degli Studi di Padova = University of Padua (Unipd), MitoVasc - Physiopathologie Cardiovasculaire et Mitochondriale (MITOVASC), Damage and Repair in Cancer Development and Cancer Treatment (DARE), and Guided Treatment in Optimal Selected Cancer Patients (GUTS)
- Subjects
Male ,Pediatrics ,PHEOCHROMOCYTOMA ,MEDULLARY-THYROID CARCINOMA ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,[SDV]Life Sciences [q-bio] ,Medizin ,Adrenal Gland Neoplasms ,Multiple Endocrine Neoplasia Type 2b ,Internal Medicine ,Endocrinology ,surgery ,0302 clinical medicine ,DOMAIN ,030212 general & internal medicine ,Child ,MUTATION ,men2 ,Middle Aged ,Prognosis ,Penetrance ,CANCER ,3. Good health ,Diabetes and Metabolism ,Natural history ,Survival Rate ,Child, Preschool ,RET PROTOONCOGENE ,MANAGEMENT ,Cohort ,Thyroidectomy ,Female ,Multiple endocrine neoplasia type 2b ,Adult ,medicine.medical_specialty ,Adolescent ,030209 endocrinology & metabolism ,Pheochromocytoma ,03 medical and health sciences ,Young Adult ,medicine ,Humans ,Thyroid Neoplasms ,Survival rate ,Retrospective Studies ,adrenal gland ,business.industry ,Infant ,International Agencies ,Retrospective cohort study ,medicine.disease ,Carcinoma, Neuroendocrine ,MEN2b ,business ,Follow-Up Studies - Abstract
© 2019 Elsevier Ltd. All rights reserved., Background: Multiple endocrine neoplasia type 2B is a rare syndrome caused mainly by Met918Thr germline RET mutation, and characterised by medullary thyroid carcinoma, phaeochromocytoma, and extra-endocrine features. Data are scarce on the natural history of multiple endocrine neoplasia type 2B. We aimed to advance understanding of the phenotype and natural history of multiple endocrine neoplasia type 2B, to increase awareness and improve detection. Methods: This study was a retrospective, multicentre, international study in patients carrying the Met918Thr RET variant with no age restrictions. The study was done with registry data from 48 centres globally. Data from patients followed-up from 1970 to 2016 were retrieved from May 1, 2016, to May 31, 2018. Our primary objectives were to determine overall survival, and medullary thyroid carcinoma-specific survival based on whether the patient had undergone early thyroidectomy before the age of 1 year. We also assessed remission of medullary thyroid carcinoma, incidence and treatment of phaeochromocytoma, and the penetrance of extra-endocrine features. Findings: 345 patients were included, of whom 338 (98%) had a thyroidectomy. 71 patients (21%) of the total cohort died at a median age of 25 years (range
- Published
- 2019
- Full Text
- View/download PDF